Exact Sciences (EXAS) Presents Data On Blood-Based Test For Detection Of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation
Go back to Exact Sciences (EXAS) Presents Data On Blood-Based Test For Detection Of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation| Exact Sciences Corp (NASDAQ: EXAS) | Delayed: 63.24 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $63.24 | 52 Week High | $22.80 | |||
| Open | $63.24 | 52 Week Low | $4.67 | |||
| Day High | $63.24 | P/E | N/A | |||
| Day Low | $63.24 | EPS | $-0.69 | |||
| Volume | 562 | |||||
